Pharma BD Deal Intelligence
Summit Therapeutics signs agreement to sell Phase III asset ridinilazole to Biossil for $500K upfront plus up to $104.5M in milestones and tiered royalties.
Summit Therapeutics signs ridinilazole deal worth up to $104.5M; asset sale lets Summit focus on oncology.
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Summit Therapeutics agreed to sell its Phase 3 precision antibiotic ridinilazole to Toronto-based, AI-native biopharma Biossil, Inc., announced July 15, 2026. Biossil pays $500,000 upfront plus up to $104.5 million in regulatory and commercial milestones and tiered royalties on future net sales. Ridinilazole, a narrow-spectrum antibiotic previously evaluated in Summit's Phase 3 Ri-CoDIFy program for Clostridioides difficile infection, is a non-core asset for Summit, which is prioritizing its oncology strategy; Biossil intends to advance the late-stage program in a high-unmet-need indication.
← Browse all deals · How we score deals
More: 2026 deals